Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
精准癌症医学中肿瘤依赖性的系统识别和药理学靶向
基本信息
- 批准号:9977981
- 负责人:
- 金额:$ 129.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAffectAnaplastic MeningiomaAreaBiochemicalBiological AssayBiological MarkersBladder AdenocarcinomaCancer ModelCancer PatientCategoriesCell CommunicationCell LineCellsClinicalClonal ExpansionColonCombined Modality TherapyComplexDataDependenceDisease ResistanceDrug CombinationsDrug TargetingDrug resistanceEngineeringEpigenetic ProcessFDA approvedGastrointestinal Stromal TumorsGeneticGenetic TranscriptionGlioblastomaGoalsHumanImmune systemIn VitroIndividualInvestigationInvestigational DrugsLung AdenocarcinomaMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMethodologyModelingMolecular ProfilingMutationNetwork-basedOncogenesOncologyOncoproteinsOrganoidsPathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePhenotypePrimary NeoplasmProgression-Free SurvivalsPropertyProteinsRegulationRelapseReporterResearch PersonnelRoleSamplingSolid NeoplasmSystemTestingTherapeuticUniversitiesValidationXenograft ModelXenograft procedurebasecandidate identificationdrug sensitivityfallsfollow-upimmune checkpointin vivoin vivo Modelindividual patientinhibitor/antagonistleukemia/lymphomamalignant breast neoplasmmolecular markerneoplastic cellnew therapeutic targetpartial responsepatient biomarkerspersonalized approachphase 3 studypopulation stratificationprecision oncologyresistance mechanismsmall molecule inhibitorsuccesstargeted cancer therapytargeted treatmenttherapeutic targettranscriptome sequencingtumortumorigenesistumorigenic
项目摘要
PROJECT SUMMARY
Successful targets for cancer therapy fall in three main categories: oncogenes that elicit tumor-specific
essentiality because of their direct role in tumorigenesis (oncogene dependency), proteins that elicit synthetic
lethality with specific mutations despite lack of a direct role in tumorigenesis (non-oncogene dependency), and
proteins related to the interaction of tumor cells with the immune system (immune-checkpoint dependency).
However, given our current understanding of cancer as a complex and highly heterogeneous system, it is
difficult to imagine that an individual protein may represent an effective target for all the billions of cells that
make up a typical mass. Indeed, while genetic-based targeted therapy and immunoncology hold great promise
a majority of patients still does not respond or will eventually relapse with drug resistant tumors, suggesting
that the concept of therapeutic targets as single proteins may need to be revisited.
To accomplish this goal, we will leverage a highly successful framework developed by our center investigators
for the identification and pharmacological targeting of tumor dependencies implemented by the concerted
activity of a handful of Master Regulator (MR) proteins within tightly regulated tumor checkpoint modules.
Specifically, we will elucidate and experimentally validate MR proteins and associated Tumor Checkpoint
modules of rare and incurable malignancies, on an individual patient basis, by performing network-based
analysis of tumor samples signatures using regulatory models reverse engineered from primary tumor
samples. We will then prioritize a set of FDA approved drugs and late stage investigational drugs in phase II or
phase III studies in oncology (oncology drugs) based on their ability to either target essential/synthetic-lethal
MRs (OncoTarget) or to reverse the full MR signature of a tumor (OncoTreat).
RNASeq profiles of appropriately matched tumor models perturbed with available oncology drugs will be
obtained and analyzed to assess the differential tumor checkpoint activity induced by individual drugs and drug
combinations, followed by low-throughput studies to elucidate the regulatory basis of their activity. Models –
including cell lines, short-term organotypic culture from tumor explants (EXPL), organoids (ORG), and patient
derived xenografts (PDX) – will be selected based on MR protein conservation. We will validate these findings
as well as overall efficacy of prioritized drugs and combinations, pharmacodynamic properties, biomarker
accuracy and sensitivity, and mechanisms of resistance in suitable in vitro and in vivo models.
If successful, this would represent the first mechanistic approach for precision cancer medicine, where
therapeutic targets, associated inhibitors, and population stratification biomarkers are systematically derived
from precise, mechanistic understanding of tumor state regulation and of its drug-induced modulation.
项目总结
癌症治疗的成功靶点分为三大类:引发肿瘤特异性的癌基因
由于它们在肿瘤发生中的直接作用(癌基因依赖性),导致合成的蛋白质具有重要意义
特定突变的致命性,尽管在肿瘤发生中缺乏直接作用(非癌基因依赖),以及
与肿瘤细胞与免疫系统相互作用相关的蛋白质(免疫检查点依赖)。
然而,鉴于我们目前对癌症作为一个复杂和高度异质系统的理解,它是
很难想象一种单独的蛋白质可能代表着所有数十亿个细胞的有效靶点
组成一个典型的团块。事实上,尽管基于基因的靶向治疗和免疫肿瘤学有着巨大的希望
大多数患者对耐药肿瘤仍然没有反应或最终会复发,这表明
将治疗靶点作为单一蛋白质的概念可能需要重新考虑。
为了实现这一目标,我们将利用我们中心调查人员开发的非常成功的框架
用于识别和药理学靶向的肿瘤依赖性实施的协调
在严格调控的肿瘤检查点模块中,少数主调节蛋白(MR)的活性。
具体地说,我们将阐明和实验验证mr蛋白和相关的肿瘤检查点。
罕见和不可治愈的恶性肿瘤模块,以患者个人为基础,通过基于网络的
利用原发肿瘤反向工程调控模型分析肿瘤样本信号
样本。然后,我们将在第二阶段或第二阶段优先考虑FDA批准的一组药物和后期研究药物
肿瘤学(肿瘤学药物)的第三阶段研究,基于其靶向基本/合成致命的能力
MRS(肿瘤靶向)或逆转肿瘤的完整MR信号(OncoTreat)。
被可用的肿瘤药物干扰的适当匹配的肿瘤模型的RNAseq图谱将是
获取并分析以评估个别药物和药物诱导的不同肿瘤检查点活性
结合,然后进行低通量研究,以阐明其活动的调节基础。机型-
包括细胞系、肿瘤外植体的短期器官分型培养(EXPL)、器官类化合物(ORG)和患者
衍生异种移植物(PDX)-将根据MR蛋白保守性进行选择。我们将验证这些发现
以及优先考虑的药物和组合的总体疗效、药效学特性、生物标志物
在合适的体外和体内模型中,耐药的准确性和敏感性以及耐药机制。
如果成功,这将是精准癌症医学的第一个机械化方法,其中
治疗靶点、相关抑制物和群体分层生物标志物被系统地派生。
来自对肿瘤状态调节及其药物诱导调节的精确的、机械的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREA CALIFANO其他文献
ANDREA CALIFANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREA CALIFANO', 18)}}的其他基金
Center for Cancer Systems Therapeutics (CaST)
癌症系统治疗中心 (CaST)
- 批准号:
10729383 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Drug Mechanism of Action-based targeting of tumor subpopulations
基于作用的肿瘤亚群靶向药物机制
- 批准号:
10729387 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
在单细胞水平上阐明和靶向肿瘤依赖性和耐药性决定因素
- 批准号:
10505333 - 财政年份:2022
- 资助金额:
$ 129.94万 - 项目类别:
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
在单细胞水平上阐明和靶向肿瘤依赖性和耐药性决定因素
- 批准号:
10709574 - 财政年份:2022
- 资助金额:
$ 129.94万 - 项目类别:
Structural and Functional Biology-based analysis of non-oncogene cancer dependencies
基于结构和功能生物学的非癌基因癌症依赖性分析
- 批准号:
10401148 - 财政年份:2021
- 资助金额:
$ 129.94万 - 项目类别:
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
精准癌症医学中肿瘤依赖性的系统识别和药理学靶向
- 批准号:
10204929 - 财政年份:2017
- 资助金额:
$ 129.94万 - 项目类别:
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
精准癌症医学中肿瘤依赖性的系统识别和药理学靶向
- 批准号:
9750650 - 财政年份:2017
- 资助金额:
$ 129.94万 - 项目类别:
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
精准癌症医学中肿瘤依赖性的系统识别和药理学靶向
- 批准号:
9362806 - 财政年份:2017
- 资助金额:
$ 129.94万 - 项目类别:
Centers for Cancer Systems Therapeutics (CaST)
癌症系统治疗中心 (CaST)
- 批准号:
9976471 - 财政年份:2016
- 资助金额:
$ 129.94万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 129.94万 - 项目类别: